Last edition
News about "Phase 2 clinical development"
Tolerance Bio Licenses Anti-IL-33 Antibody TLB-33 from Tanabe Pharma
Tolerance Bio plans to advance TLB-33 into Phase 2 development to evaluate its potential in preserving thymic function and supporting immune resilience.
Phase 2 Clinical Development | 29/09/2026 | By News Bureau
FDA Clears Graviton BioScience's GV101 for Phase 2 Development in Friedreich's Ataxia
Graviton BioScience has received FDA IND clearance for a new GV101 capsule formulation, paving the way for a Phase 2 trial in patients with Friedreich’s ataxia.
Phase 2 Clinical Development | 12/08/2026 | By News Bureau | 385
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy